1. Antibiotic utilization and Pseudomonas aeruginosa resistance in intensive care units
- Author
-
Vladimíra, Vojtová, Milan, Kolár, Kristýna, Hricová, Radek, Uvízl, Jan, Neiser, Ladislav, Blahut, and Karel, Urbánek
- Subjects
Piperacillin ,Tazobactam ,Cefoperazone ,Penicillanic Acid ,Microbial Sensitivity Tests ,Ceftazidime ,Anti-Bacterial Agents ,Intensive Care Units ,Sulbactam ,Ciprofloxacin ,Drug Resistance, Multiple, Bacterial ,Pseudomonas aeruginosa ,Gentamicins ,Amikacin ,Czech Republic - Abstract
Pseudomonas aeruginosa is one of the most frequent and dangerous pathogens involved in the etiology of severe nosocomial infections. A retrospective observational study was conducted at all intensive care units of the University Hospital in Olomouc, Czech Republic (155 ICU beds). Complete antibiotic utilization data of the ICUs in the period of 1999 to 2008 were processed according to ATC/DDD system and expressed in defined daily doses per 100 bed-days (DBD). Utilization of meropenem, imipenem, ciprofloxacin, ofloxacin, pefloxacin, gentamicin, amikacin, ceftazidime, cefoperazone, cefoperazone/sulbactam and piperacillin/tazobactam was measured. Pseudomonas aeruginosa strains were isolated from clinical material obtained from patients hospitalized in ICUs. During the ten-year period, utilization of the entire group of antibiotics monitored grew. It increased from 23.52 DBD in 1999 to 27.48 DBD in 2008 with a peak of 33.04 DBD in 2007. P. aeruginosa accounted for as much as 42% of pneumonias and 23% of surgical wound infections. Our results show that P. aeruginosa strains became gradually resistant to all antibiotics used in the treatment of the infections caused by them, with the exception of amikacin and piperacillin/tazobactam.
- Published
- 2011